Ibrutinib and Venetoclax for First-Line Treatment of CLL

Affiliations

¹ Amsterdam University Medical Centers, Amsterdam, the Netherlands a.p.kater@amsterdamumc.nl.
² Albert Schweitzer Hospital, Dordrecht, the Netherlands.
³ Rigshospitalet, Copenhagen, Denmark.

Comment

Arnon P Kater et al. N Engl J Med. 2019.

. 2019 Aug 22;381(8):788-789.

doi: 10.1056/NEJMc1908754.

¹ Amsterdam University Medical Centers, Amsterdam, the Netherlands a.p.kater@amsterdamumc.nl.
² Albert Schweitzer Hospital, Dordrecht, the Netherlands.
³ Rigshospitalet, Copenhagen, Denmark.

No abstract available

Comment in

Ibrutinib and Venetoclax for First-Line Treatment of CLL. Reply.
Jain N, Gandhi V, Wierda W. Jain N, et al. N Engl J Med. 2019 Aug 22;381(8):789. doi: 10.1056/NEJMc1908754. N Engl J Med. 2019. PMID: 31433937 No abstract available.

Ibrutinib and Venetoclax for First-Line Treatment of CLL.
Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Jain N, et al. N Engl J Med. 2019 May 30;380(22):2095-2103. doi: 10.1056/NEJMoa1900574. N Engl J Med. 2019. PMID: 31141631 Free PMC article. Clinical Trial.